CRA - I've been waiting for news like this, although I have no idea if it will even affect the "Coney Island" stock as hjz calls it. <g>
But this is how they will be making money and soon I'm sure there will be many more subscribers. Subscriptions are supposedly in the millions.
Celera Genomics to Provide First Academic Subscription to Vanderbilt University; First Subscriber to Use Web-Based Celera Discovery System
================================================================
ROCKVILLE, Md.--(BUSINESS WIRE)--May 7, 2000--Celera Genomics
(NYSE:CRA), a PE Corporation business, announced today it signed an
agreement with Vanderbilt University that provides a five-year,
comprehensive subscription to certain Celera database products.
Vanderbilt will become the first subscriber to access Celera's
database information through its Celera Discovery System(TM) on the
World Wide Web. Financial terms of the agreement were not disclosed.
The annual subscription rates are dependent on the nature of the
subscription, size of the institution, and the number of concurrent
users.
"It is very fitting that our first academic database subscription
is with a premier medical and research institution such as
Vanderbilt," said J. Craig Venter, Ph.D., Celera's president and chief
scientific officer. "We firmly believe that researchers everywhere
should have access to our genomic database information. With our
web-based science discovery system we have provided the mechanism to
do so."
"Vanderbilt's basic science departments are routinely ranked in
the top ten in the nation year after year. Through continuing
investments like this acquisition of genomic data and tools, we think
we can provide a foundation for even more rapid growth," said Joe B.
Wyatt, Vanderbilt Chancellor.
Vanderbilt's database subscription gives its academic researchers
access until 2005 to four databases developed by Celera. All four of
Celera's databases include Celera proprietary information as well as
publicly available data. First, the Celera Human Gene Index provides
customers with the set of human genes derived from EST sequencing
programs. Second, Celera's Human Genome Database is expected to
provide the complete sequence of the human genome and the entire
collection of human genes with links to associated biological and
disease information. Third, the Drosophila Genome Database provides
the complete sequence of the Drosophila melanogaster genome sequence
generated by Celera's whole genome shotgun sequencing strategy. The
Drosophila genome database is extensively annotated with gene, protein
and biological information. Fourth, the Mouse Genome Database being
generated by Celera should allow for comparative analysis with the
human genome that may be especially significant for the identification
of genes and gene regulatory regions of importance to understanding
human biology. Access to the databases also provides Vanderbilt
researchers with associated comprehensive bioinformatics systems and
tools for viewing, browsing, and analyzing genomic information.
"We believe that Vanderbilt's subscription to Celera's databases
is validation of the importance of genomic information. We hope access
to our data will enable Vanderbilt's renowned researchers to advance
their work in genomics," said Tony L. White, PE Corporation chairman,
president and chief executive officer.
Celera Discovery System
The CeleraScience(TM) portal provides genomic and proteomic data
as well as medical news. The portal also features educational
information and access to the Celera Discovery System. The
CeleraScience portal is designed for users to access a broad array of
public news and special features by a staff of independent medical and
science writers. Through the Celera Discovery System,
subscription-based customers can access Celera's expanding databases
and analysis tools. The flexible architecture utilizes one platform to
deliver incremental levels of value depending on the subscription
level chosen by the customer. This is intended to allow Celera to
serve a variety of users including academic, biotechnology,
pharmaceutical, and public.
Essential features of the Celera's Discovery System subscriptions
include:
*T
-- Access to Celera's unique database content including
annotation, extensive computational resources, and software
tools for analysis
-- A single platform for viewing and analyzing integrated
database resources
-- Freedom for academic subscribers to publish their discoveries
and develop intellectual property on their discoveries without
royalties or "reach through" rights to Celera
-- Secure web-based access to Celera's databases
-- Value added annotation
-- Training and subscriber support
*T
Vanderbilt University is a selective, comprehensive teaching and
research university. Ten schools offer both an outstanding
undergraduate program and a full range of graduate and professional
programs. With a prestigious faculty of more than 1,700 full-time and
300 part-time members, Vanderbilt attracts a diverse student body of
approximately 5,900 undergraduates and 4,300 graduate and professional
students from all 50 states and over 90 foreign countries.
PE Corporation currently comprises two operating groups. Celera
Genomics Group, headquartered in Rockville, MD, intends to become the
definitive source of genomic and related medical information. PE
Biosystems Group, headquartered in Foster City, CA and with sales of
$1.2 billion during fiscal 1999, develops and markets instrument-based
systems, reagents, software, and contract related services to the life
science industry and research community. Information about the
company, including consolidated financial statements of PE
Corporation, is available on the World Wide Web at
pecorporation.com or by phoning (800) 762-6923.
Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or phrases
such as "believe," "expect," "anticipate," "should," "intend,"
"planned," "estimated," and "potential," among others. These
forward-looking statements are based on PE Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, PE Corporation notes that
a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. The risks and
uncertainties that may affect the operations, performance,
development, and results of Celera Genomics' businesses include but
are not limited to (1) operating losses to date; (2) a unique and
developing business plan; (3) dependence on the timely completion of
the sequencing and assembly of the human genome; (4) uncertainty of
revenue growth; (5) unproven use of genomics information to develop
products; (6) intense competition in the evolving genomics industry;
(7) dependence on customers in and subject to the risks of the
pharmaceutical and biotechnology industries; (8) heavy reliance on
strategic relationship with the PE Biosystems group; (9) potential
product liability claims; (10) liabilities related to use of hazardous
materials; (11) lengthy sales cycle; (12) dependence on the unique
expertise of its scientific and management staff; (13) uncertainty of
patent, copyright and intellectual property protection; (14)
dependence on computer hardware, software, and internet applications;
(15) access to biological materials; (16) legal, ethical and social
issues affecting demand for products; (17) disruptions caused by rapid
growth of the business; (18) government regulation of its products and
services; (19) risks of future acquisitions; and (20) other factors
that might be described from time to time in PE Corporation's filings
with the Securities and Exchange Commission.
Copyright (c) 2000. PE Corporation. All Rights Reserved.
Celera, Celera Genomics, Celera Discovery System, CeleraScience,
and PE Biosystems are trademarks of PE Corporation.
|
